Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
5.19
-0.02 (-0.38%)
Aug 26, 2026, 12:30 PM EDT - Market open
Oramed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 2 | - | 1.34 | 2.7 | 2.71 | |
Revenue Growth | - | - | - | -50.42% | -0.33% | 0.33% |
Cost of Revenue | - | 1.99 | - | - | - | - |
Gross Profit | - | 0.01 | - | 1.34 | 2.7 | 2.71 |
Selling, General & Admin | 9.79 | 8.72 | 6.46 | 8.14 | 15.66 | 12.58 |
Research & Development | 4.74 | 6.38 | 6.32 | 8.97 | 27.64 | 27.11 |
Operating Expenses | 14.52 | 15.1 | 12.78 | 17.11 | 43.3 | 39.69 |
Operating Income | -14.52 | -15.09 | -12.78 | -15.77 | -40.6 | -36.98 |
Interest Expense | - | - | -0.85 | -2.04 | - | - |
Interest & Investment Income | 1.37 | 2.37 | 4.98 | 8.17 | 3.57 | 0.47 |
Currency Exchange Gain (Loss) | -0.44 | -0.25 | 0.17 | -0.12 | 0.18 | -0.03 |
Other Non Operating Income (Expenses) | 8.99 | 0.35 | -0.03 | -1.54 | -0.01 | -0.01 |
EBT Excluding Unusual Items | -4.61 | -12.62 | -8.5 | -11.3 | -36.86 | -36.55 |
Gain (Loss) on Sale of Investments | 224.88 | 87.94 | -7.42 | 16.39 | -0.81 | -0.22 |
Pretax Income | 220.28 | 75.32 | -15.92 | 5.09 | -37.66 | -36.77 |
Income Tax Expense | 45.41 | 11.31 | 3.18 | - | 0.1 | - |
Earnings From Continuing Operations | 174.86 | 64.02 | -19.1 | 5.09 | -37.76 | -36.77 |
Minority Interest in Earnings | 0.01 | 0.03 | 0.04 | 0.44 | 1.2 | 1.76 |
Net Income | 174.87 | 64.05 | -19.06 | 5.53 | -36.56 | -35 |
Preferred Dividends & Other Adjustments | 0.81 | 0.81 | - | - | - | - |
Net Income to Common | 174.06 | 63.24 | -19.06 | 5.53 | -36.56 | -35 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 41 | 41 | 41 | 40 | 39 | 37 |
Shares Outstanding (Diluted) | 42 | 42 | 41 | 41 | 39 | 37 |
Shares Change | 2.31% | 3.84% | 0.70% | 4.02% | 5.08% | 30.36% |
EPS (Basic) | 4.23 | 1.53 | -0.47 | 0.14 | -0.94 | -0.94 |
EPS (Diluted) | 4.15 | 1.50 | -0.48 | 0.14 | -0.94 | -0.94 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -5.22 | -9.15 | -8.43 | -10.55 | -28.41 | -33.39 |
Free Cash Flow Per Share | -0.12 | -0.22 | -0.21 | -0.26 | -0.73 | -0.90 |
Gross Margin | - | 0.65% | - | 100.00% | 100.00% | 100.00% |
Operating Margin | - | -754.40% | - | -1176.79% | -1501.96% | -1363.50% |
Profit Margin | - | 3162.10% | - | 412.31% | -1352.61% | -1290.71% |
Free Cash Flow Margin | - | -457.70% | - | -787.24% | -1051.20% | -1231.31% |
EBITDA | -14.4 | -14.97 | -12.59 | -15.57 | -40.54 | -36.92 |
D&A For EBITDA | 0.12 | 0.12 | 0.19 | 0.2 | 0.06 | 0.05 |
EBIT | -14.52 | -15.09 | -12.78 | -15.77 | -40.6 | -36.98 |
Effective Tax Rate | 20.62% | 15.01% | - | - | - | - |